ArticleSpinal cord2026
Dual evidence reveals the therapeutic efficacy of exosome-delivered miR-124-3p in spinal cord injury via a novel CTDSP1/WNT/β-catenin mechanism.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designIntegrated preclinical systematic review and meta-analysis with basic experimental research.
objectivesTo evaluate the therapeutic efficacy of miR-124-3p in spinal cord injury (SCI) repair and elucidate its mechanism involving the CTDSP1/WNT/β‑catenin axis.
settingUniversity-based laboratory in Lanzhou, China.
methodsA meta‑analysis of five animal studies assessed the effects of miR‑124‑3p. In vitro, a lipopolysaccharide‑injured PC12 cell model was treated with exosomes derived from miR‑124‑3p‑overexpressing human umbilical cord mesenchymal stem cells. Mechanistic validation included dual‑luciferase reporter assay, qPCR, Western blot, and pathway inhibition/rescue experiments.
resultsThe meta‑analysis showed that miR‑124‑3p significantly improved motor function, reduced glial scar marker GFAP and pro‑inflammatory cytokines, and increased neuronal/axonal markers (Map2, NF200, NeuN). Mechanistically, miR‑124‑3p directly targeted the 3'‑UTR of CTDSP1. Exosome‑delivered miR‑124‑3p downregulated CTDSP1, activated WNT/β‑catenin signaling, suppressed GFAP/CSPG, and promoted β‑tubulin III, NeuN, and NF200 expression. These effects were reversed by the WNT inhibitor MSAB and mimicked by a CTDSP1 inhibitor.
conclusionsmiR‑124‑3p promotes SCI repair primarily by targeting CTDSP1 to activate the WNT/β‑catenin pathway, thereby inhibiting glial scarring and enhancing neuronal survival/regeneration. This mechanism supports the therapeutic potential of combined exosome and miRNA strategies.
Indexed as
Identifiers
42249107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.